SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences - Quaterly Results

17 May 2023 Evaluate
The Revenue for the quarter ended  March 2023 of Rs. 3145.84 millions grew by 11.50 % from Rs. 2821.42 millions.Net profit showed a marginal rise at Rs. 878.41 millions for the quarter ended March 2023, as compared to corresponding quarter of last year.Operating profit surged to 1157.50 millions from the corresponding previous quarter of 1106.76 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 3145.84 2821.42 11.50 13307.25 12157.30 9.46 13307.25 12157.30 9.46
Other Income 42.60 90.52 -52.94 172.64 289.89 -40.45 172.64 289.89 -40.45
PBIDT 1157.50 1106.76 4.58 5223.78 5129.84 1.83 5223.78 5129.84 1.83
Interest 29.56 9.77 202.56 208.10 29.91 595.75 208.10 29.91 595.75
PBDT 1127.94 1096.99 2.82 5015.68 5099.93 -1.65 5015.68 5099.93 -1.65
Depreciation 172.84 150.70 14.69 646.57 514.55 25.66 646.57 514.55 25.66
PBT 955.10 946.29 0.93 4369.11 4585.38 -4.72 4369.11 4585.38 -4.72
TAX 76.69 79.20 -3.17 389.03 413.46 -5.91 389.03 413.46 -5.91
Deferred Tax -93.36 6.24 -1596.15 -375.93 -388.26 -3.18 -375.93 -388.26 -3.18
PAT 878.41 867.09 1.31 3980.08 4171.92 -4.60 3980.08 4171.92 -4.60
Equity 135.99 135.93 0.04 135.99 135.93 0.04 135.99 135.93 0.04
PBIDTM(%) 36.79 39.23 -6.20 39.26 42.20 -6.97 39.26 42.20 -6.97

Eris Lifesciences Share Price

1446.50 -18.90 (-1.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×